It's curtains for BI's Gilotrif in breast cancer
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's dual tyrosine kinase inhibitor has failed in two trials in breast cancer, signalling the end of its bid to add this indication to the drug's roster.